WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Biomarin Pharmaceutical earnings were $268.7M for the trailing 12 months ending Mar 31, 2026, with -49.1% growth year over year. The latest BMRN earnings report on Mar 31, 2026 announced Q1 2026 earnings of $105.5M, down 326.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BMRN reported annual earnings of $348.9M, with -18.3% growth. The next BMRN earnings date is Aug 3, 2026.

BMRN past earnings growth

How has BMRN's earnings growth performed historically?

Company
-49.09%
Industry
49%
Market
83.56%
BMRN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BMRN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
BMRN's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

BMRN earnings history

Current Revenue
$3.2B
Current Earnings
$268.7M
Current Profit Margin
8.3%

BMRN Return on Equity

Current Company
4.4%
Current Industry
-141.9%
Current Market
13.5%
BMRN's Return on Equity (4.4%)... subscribe to Premium to read more.
High Return on Equity Performance

BMRN Return on Assets

Current Company
3.4%
Current Industry
-13.7%
BMRN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BMRN announces earnings.

BMRN Return on Capital Employed

Current Company
5.24%
Current Industry
-9.5%
BMRN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BMRN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BMRN$482.49M$268.74M-20.32%$1.40
SMMT-$1.21B-$1.21BN/A-$0.02
KRYS$213.96M$225.03M+97.84%$7.75
CYTK-$767.18M-$829.61MN/A-$6.84
NUVL-$449.48M-$450.07MN/A-$6.06
View Top Biotech Stocks

BMRN earnings dates

Next earnings date
Aug 3, 2026

Biomarin Pharmaceutical Earnings Reports & History FAQ

What were Biomarin Pharmaceutical's earnings last quarter?

On BMRN's earnings call on Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q1 2026 earnings per share (EPS) of $0.55, up 43.3% year over year. Total BMRN earnings for the quarter were $105.53 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was $0.97.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

When does Biomarin Pharmaceutical report earnings?

The next BMRN earnings call is Invalid Date. Add BMRN to your watchlist to be reminded of Biomarin Pharmaceutical's next earnings date.

Is Biomarin Pharmaceutical profitable or losing money?

As of the last Biomarin Pharmaceutical earnings report, Biomarin Pharmaceutical is currently profitable. Biomarin Pharmaceutical's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $268.74 million, a 48.7% decrease year over year.

What was BMRN's earnings growth in the past year?

As of Biomarin Pharmaceutical's earnings date in Invalid Date, Biomarin Pharmaceutical's earnings has grown -49.09% year over year. This is 98.09 percentage points lower than the US Biotechnology industry earnings growth rate of 49%. BMRN earnings in the past year totalled $268.74 million.

What are Biomarin Pharmaceutical's earnings expectations?

The current EPS estimate for Biomarin Pharmaceutical's earnings report in Invalid Date is $0.96.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.